Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride provides potassium ions essential for maintenance of cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose 5% supplies calories and may reduce protein and nitrogen losses. Sodium chloride 0.3% supplies sodium and chloride ions to maintain electrolyte balance.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Treatment and prevention of hypokalemia,Maintenance of electrolyte balance when oral replacement is not feasible,Correction of potassium deficiency associated with diuretic therapy or other conditions
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous infusion: 10-20 m Eq/hour, not exceeding 30 m Eq/hour or 200 m Eq/24 hours; rate depends on severity of hypokalemia and patient tolerance.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Not applicable as potassium is an electrolyte regulated by renal function; in normal renal function, steady state achieved within 24-48 hours of continuous infusion
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Potassium is primarily excreted by the kidneys; metabolism not applicable. Dextrose undergoes glycolysis and oxidation to carbon dioxide and water. Sodium chloride does not undergo metabolism.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal: >90% as potassium ions; minimal biliary/fecal (<5%)
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Minimal; potassium ions are not significantly protein-bound (<5%)
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Approximately 0.5 L/kg; represents total body water distribution; clinical note: ~98% intracellular, 2% extracellular
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Oral (if applicable): 100% (well absorbed); IV: 100%
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 50%; GFR < 10 m L/min: avoid or use with extreme caution, reduce dose by 75%.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No specific adjustment required; monitor for acidosis in severe hepatic impairment.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Intravenous infusion: 0.5-1 m Eq/kg/day, maximum rate 1 m Eq/kg/hour; not to exceed 30 m Eq/day in neonates.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Use lower initial doses; monitor renal function and serum potassium closely; avoid rapid infusion due to increased risk of hyperkalemia.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
Concentrated potassium chloride injections are contraindicated and must be diluted prior to administration. Rapid intravenous administration may cause fatal hyperkalemia and cardiac arrest. Do not administer undiluted.
None.
Monitor serum potassium levels and ECG frequently during administration. Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia. Avoid rapid infusion; may cause local venous irritation. Do not use plastic container in series connections.
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hyperkalemia, severe renal failure, untreated Addison's disease, severe hemolytic reactions, hyperkalemia due to any cause, or known hypersensitivity to any component.
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
Avoid high-potassium foods (e.g., bananas, oranges, potatoes, spinach, tomatoes, salt substitutes) unless directed by clinician, as excessive intake can lead to hyperkalemia. Grapefruit juice has no significant interaction with potassium chloride but caution with other medications. Dextrose content (5%) may affect glycemic control in diabetics; monitor blood glucose.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Potassium chloride administration is not considered teratogenic. Normal electrolyte balance is critical for fetal development; however, hyperkalemia or hypokalemia may lead to adverse fetal effects. Potassium supplementation should be used to correct hypokalemia, avoiding both deficiency and excess. No specific malformations are attributed to potassium chloride. First trimester: No known risks when used appropriately. Second and third trimesters: Use as needed to maintain normal potassium levels; overdose may cause fetal arrhythmias.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Breastfeeding safety: Potassium chloride is a normal component of breast milk. Supplementation to correct maternal deficiency is considered safe. M/P ratio: Not available; potassium is actively transported into milk, but maternal dose does not significantly affect infant serum levels. Caution with high doses due to potential for maternal hyperkalemia.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Pharmacokinetics of potassium are altered in pregnancy due to increased renal blood flow and GFR, leading to enhanced clearance. Therefore, higher doses may be required to achieve target serum levels in hypokalemic pregnant women. However, dosing must be individualized based on serum potassium monitoring; no fixed dose adjustment recommendation exists. Caution to avoid hyperkalemia, especially in preeclampsia or renal impairment.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Always confirm patency of IV line before infusion due to risk of phlebitis and extravasation. Monitor serum potassium and cardiac telemetry during infusion, especially in patients with renal impairment or on digoxin. Do not administer IV potassium undiluted or via bolus; maximum infusion rate is 10 m Eq/hour via peripheral line, 20 m Eq/hour via central line. In patients with severe hypokalemia (<2.5 m Eq/L), consider continuous cardiac monitoring and more aggressive replacement under ICU setting. Note that dextrose-containing solutions may transiently lower serum potassium via insulin-mediated cellular shift.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This medication is given through a vein (IV) to replace potassium and provide fluids.,Report any pain, redness, or swelling at the IV site immediately.,Inform your doctor if you have kidney problems, heart disease, or are taking digoxin or diuretics.,You may need regular blood tests to check your potassium levels and kidney function.,Do not consume potassium-rich foods or supplements unless advised by your doctor, as it may cause dangerously high potassium levels.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER is a Electrolyte that works by Potassium chloride provides potassium ions essential for maintenance of cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose 5% supplies calories and may reduce protein and nitrogen losses. Sodium chloride 0.3% supplies sodium and chloride ions to maintain electrolyte balance.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER is: Intravenous infusion: 10-20 m Eq/hour, not exceeding 30 m Eq/hour or 200 m Eq/24 hours; rate depends on severity of hypokalemia and patient tolerance.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER is classified as Category A/B. Potassium chloride administration is not considered teratogenic. Normal electrolyte balance is critical for fetal development; however, hyperkalemia or hypokalemia may lead to adve. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.